Pharvaris (NASDAQ:PHVS - Get Free Report) shares gapped up prior to trading on Tuesday . The stock had previously closed at $17.06, but opened at $17.89. Pharvaris shares last traded at $17.52, with a volume of 6,706 shares traded.
Analyst Ratings Changes
A number of equities research analysts have commented on the stock. Cantor Fitzgerald started coverage on shares of Pharvaris in a report on Tuesday. They set an "overweight" rating and a $28.00 price objective on the stock. JMP Securities raised their price target on Pharvaris from $46.00 to $55.00 and gave the company a "market outperform" rating in a report on Friday, January 31st.
View Our Latest Report on Pharvaris
Pharvaris Stock Up 0.1 %
The business has a fifty day moving average of $15.04 and a 200 day moving average of $18.06. The firm has a market cap of $934.16 million, a P/E ratio of -6.38 and a beta of -2.84.
Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its quarterly earnings results on Monday, April 7th. The company reported ($0.68) earnings per share for the quarter, beating analysts' consensus estimates of ($0.74) by $0.06. On average, sell-side analysts expect that Pharvaris will post -2.71 EPS for the current fiscal year.
Institutional Investors Weigh In On Pharvaris
A number of hedge funds and other institutional investors have recently made changes to their positions in PHVS. Legal & General Group Plc increased its holdings in Pharvaris by 11.2% during the fourth quarter. Legal & General Group Plc now owns 9,855 shares of the company's stock worth $189,000 after buying an additional 994 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Pharvaris by 3.7% in the 4th quarter. Geode Capital Management LLC now owns 38,333 shares of the company's stock valued at $735,000 after purchasing an additional 1,356 shares during the period. Deutsche Bank AG grew its holdings in Pharvaris by 13.0% during the fourth quarter. Deutsche Bank AG now owns 18,168 shares of the company's stock worth $348,000 after purchasing an additional 2,087 shares during the period. JPMorgan Chase & Co. increased its position in Pharvaris by 1,125.3% during the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock worth $59,000 after buying an additional 2,847 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new stake in Pharvaris in the fourth quarter valued at approximately $64,000.
About Pharvaris
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Read More
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
